JRI Orthopaedics breaks into Chinese market

2nd September 2015

A multi-award winning Yorkshire healthcare company is celebrating 45 years in business by breaking into the Chinese market.

JRI Orthopaedics has secured a contract to produce hip replacement implants in its Sheffield manufacturing facility for a Beijing-based medical company to sell into the Chinese market. JRI, which manufactures orthopaedic implants and surgical instruments, is also hoping to have its own hip replacement products registered for sale in China early next year and has a distribution deal lined up with its Chinese partner. Managing Director Keith Jackson said: -Despite the fact that China leads the world in low cost manufacturing, our world class manufacturing capabilities and efficiencies have allowed us to defy conventions. -The Chinese economy is huge and significant investment is being made in health care. Patient expectations are increasing and there is a really good appetite for innovative British brands. -Our Chinese partner believes that being able to offer quality British manufactured products at competitive prices will give them a significant advantage, over both other Chinese companies and the US-based multi-nationals currently selling into the hip replacement segment of the rapidly growing orthopaedic implants market in China. Initial contacts were made when Keith was invited on the biggest trade mission from the UK to China in 2013, led by the Prime Minister. Keith added: -We are now manufacturing products in Sheffield that were designed in China and will be used to treat Chinese patients. -The Chinese regulatory approvals for our products are well advanced and we have a great partner company in China to promote the JRI brand in China as soon as we achieve this. JRI Orthopaedics, winner of the coveted marquee prize at the 2015 Made In Sheffield Awards, operates from a state-of-the-art manufacturing base in Chapeltown. The company, founded 45 years ago by renowned orthopaedic surgeon Mr Ronald Furlong, has the declared purpose of giving patients a better quality of life for longer by providing the best solutions in joint reconstruction, repair and regeneration. It became the first in the world to use a hydroxyapatite ceramic (H-A.C) coating on hip replacements. H-A.C is a synthetic version of the natural mineral present in bones and, by perfecting the coating process, JRI was able to produce an implant that bonds biologically with the patient's own bone. JRI's revolutionary Furlong H-A.C Hip has achieved exceptional clinical results over the last 30 years and is recognized as the best performing uncemented hip implant on the market. Keith added: -Over 250,000 patients have benefited from this technology giving the recipients the real prospect of a hip for life. -The company was founded through innovation and this is still hugely important to JRI. We have a very active innovation programme and collaborate with leading centres across Europe on cutting edge research and product development. The focus on research and the development of innovative orthopaedic treatments is part of JRI's unique company structure. It is wholly owned by the charity Orthopaedic Research UK (ORUK), and Gift Aids the majority of its profits to ORUK to fund independent research and medical education - £12m over the last 10 years alone.

You might also be interested in

BCC responds to opening of points-based immigration system

Wed 2nd December 2020

Commenting on the opening of the government’s points-based immigration system, BCC Head of People Policy Jane Gratton said:??

BCC responds to opening of points-based immigration system

Tue 1st December 2020

Commenting on the opening of the government’s points-based immigration system, BCC Head of People Policy Jane Gratton said:

BCC responds to new tiered Coronavirus restrictions

Thu 26th November 2020

Commenting on the new tiered Coronavirus restrictions that will come into effect after the lockdown ends in England on December 2, BCC Director General Adam Marshall said:

BCC responds to the Chancellor’s Spending Review

Wed 25th November 2020

Commenting on the Chancellor’s Spending Review, BCC Director General Adam Marshall said: